Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Torrent Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting at Rs 3155.2, up 0.03% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.46% on the day, quoting at 25117.25. The Sensex is at 82511.15, up 0.39%. Torrent Pharmaceuticals Ltd has dropped around 2.55% in last one month.
Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has dropped around 3.24% in last one month and is currently quoting at 21684.4, up 0.47% on the day. The volume in the stock stood at 42060 shares today, compared to the daily average of 3.5 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 3167.7, up 0.38% on the day. Torrent Pharmaceuticals Ltd is up 10.17% in last one year as compared to a 7.99% gain in NIFTY and a 10.18% gain in the Nifty Pharma index.
The PE of the stock is 56.03 based on TTM earnings ending March 25.
RBL Bank and Manappuram Finance shares are banned from F&O Trading on 21 May 2025.
Upcoming Results:
IndusInd Bank, Oil & Natural Gas Corporation (ONGC), Astral, Colgate Palmolive (India), H.G. Infra Engineering, InterGlobe Aviation, Ircon International, Mankind Pharma, National Aluminium Co, NTPC Green Energy, Oil India, Power Finance Corp, Rail Vikas Nigam, Trident, VRL Logistics will declare their results later today.
Stocks to Watch:
Dixon Technologies (India)’s consolidated net profit surged 321.2% to Rs 400.82 crore on 121% jump in revenue from operations to Rs 10,292.54 crore in Q4 FY25 over Q4 FY24.
Torrent Pharmaceuticals reported 10.9% jump in consolidated net profit to Rs 498 crore on 7.9% increase in revenue from operations to Rs 2,909 crore in Q4 FY25 over Q4 FY24.
United Spirits’ consolidated net profit jumped 74.7% to Rs 421 crore on 8.9% increase in net sales (excluding excise duty) to Rs 3,031 crore in Q4 March 2025 over Q4 March 2024.
Gland Pharma’s consolidated net profit declined 3.1% to Rs 186.54 crore in Q4 FY25, compared with Rs 192.42 crore in Q4 FY24. Revenue from operations fell 7.3% YoY to Rs 1,424.91 crore in Q4 FY25.
Aster DM Healthcare reported consolidated net profit of Rs 79.02 crore in Q4 FY25 compared with net loss of Rs 24.03 crore in Q4 FY24.Revenue from operations increased 2.7% YoY to Rs 1,000.34 crore during the quarter ended 31st March 2025.
J kumar Infraprojects’ consolidated net profit rose 12.1% to Rs 114.20 crore on 14.6% jump in revenue from operations to Rs 1,632.74 crore in Q4 FY25 over Q4 FY24.
Senores Pharmaceuticals (SPL)‘s US subsidiary, Senores Pharmaceuticals US has entered into an agreement to acquire US FDA- approved ANDA for Enalapril Maleate Tablets from Wockhardt. Enalapril is used for treatment of hypertension, heart failure.
For the full year,net profit rose 15.40% to Rs 1911.00 crore in the year ended March 2025 as against Rs 1656.00 crore during the previous year ended March 2024. Sales rose 7.15% to Rs 11317.00 crore in the year ended March 2025 as against Rs 10562.00 crore during the previous year ended March 2024.
Torrent Pharmaceuticals Ltd, Gland Pharma Ltd, Whirlpool of India Ltd, Glaxosmithkline Pharmaceuticals Ltd are among the other stocks to see a surge in volumes on BSE today, 21 May 2025.
K P R Mill Ltd saw volume of 114.09 lakh shares by 10:46 IST on BSE, a 139.51 fold spurt over two-week average daily volume of 81780 shares. The stock dropped 5.35% to Rs.1,164.35. Volumes stood at 46792 shares in the last session.
Torrent Pharmaceuticals Ltd saw volume of 21594 shares by 10:46 IST on BSE, a 11.33 fold spurt over two-week average daily volume of 1907 shares. The stock increased 2.74% to Rs.3,332.15. Volumes stood at 1268 shares in the last session.
Gland Pharma Ltd notched up volume of 30201 shares by 10:46 IST on BSE, a 5.17 fold spurt over two-week average daily volume of 5846 shares. The stock rose 3.69% to Rs.1,551.30. Volumes stood at 13537 shares in the last session.
Whirlpool of India Ltd saw volume of 68270 shares by 10:46 IST on BSE, a 4.7 fold spurt over two-week average daily volume of 14526 shares. The stock dropped 1.07% to Rs.1,281.70. Volumes stood at 6069 shares in the last session.
Glaxosmithkline Pharmaceuticals Ltd witnessed volume of 33693 shares by 10:46 IST on BSE, a 4.57 times surge over two-week average daily volume of 7378 shares. The stock increased 6.72% to Rs.2,974.70. Volumes stood at 5430 shares in the last session.
Total revenue from operations grew 7.79% year on year (YoY) to Rs 2,959 crore in the quarter ended 31 March 2025.
Profit before tax stood at Rs 665 crore in March 2025 quarter, up 5.38% from Rs 631 crore posted in same quarter last year.
Operating EBITDA stood at Rs 964 crore in Q4 FY25, registering a growth of 9.17% as against Rs 883 crore reported in Q4 FY24. The operating EBITDA margin improved to 32.6% in Q4 FY25, up from 32.2% in the previous year.
Torrent Pharmaceuticals reported India revenues of Rs 1,545 crore in Q4 FY25, marking a 12% year-on-year growth, driven by strong performance in focus therapies. According to AIOCD secondary market data, the Indian Pharmaceutical Market (IPM) grew 8% during the quarter. Torrent's chronic segment outpaced the market, posting a 14% growth compared to IPM’s 9% rise in the same category. On a MAT (Moving Annual Total) basis, Torrent continued to outperform the industry across key therapy areas, supported by robust new product launches. The company currently has 21 brands ranked among the Top 500 in the IPM, with 14 brands clocking over Rs 100 crore in annual sales.
Brazil revenues for Torrent Pharma stood at Rs 351 crore, marking a decline of 6%, primarily impacted by the steep depreciation of the Brazilian Real (BRL). However, constant currency revenues were $ 234 million, reflecting a 5% increase. The company also faced a challenge due to a lower-than-expected annual price increase on April 1st, which led wholesalers to reduce their inventory more than usual. According to IQVIA data, Torrent grew at 13%, outperforming the market's growth of 7%. Additionally, Torrent currently has sixty-three products under review by ANVISA.
The company reported revenues of Rs 286 crore from its Germany operations in Q4 FY25, registering a 2% year-on-year growth. In constant currency terms, revenues stood at €31 million, up 1% YoY. The company attributed the modest growth to continued success in securing new tender wins, supported by ongoing cost improvement initiatives.
Torrent Pharmaceuticals reported a 15% year-on-year rise in US business revenue at Rs 302 crore for Q4 FY25. In constant currency terms, revenue stood at $35 million, marking a 10% increase compared to the same period last year.
On a full year basis, the company’s net profit rallied 15.39% to Rs 1,911 crore on 7.34% rise in total revenue from operations to Rs 11,516 crore in FY25 over FY24.
Torrent Pharmaceuticals reported strong performance in its India business for FY25, with revenues rising 13% year-on-year to Rs 6,393 crore.
In Brazil, revenue declined 2% to Rs 1,100 crore; however, in constant currency terms, it grew 9% to R$734 million.
The Germany business posted a 6% increase in revenue to Rs 1,139 crore, with constant currency growth of 5% at €126 million. Meanwhile, the US business recorded a 2% rise in revenue to Rs 1,100 crore. In constant currency, US revenue stood at $130 million, with flat growth of 1% after adjusting for one-off income in FY24.
Meanwhile, the board recommended a final dividend of Rs 6 per equity share of Rs 5 each. Earlier an interim dividend of Rs 26 per equity share was paid during the last quarter, it added.
Further, the board has approved the appointment of Aman Mehta as Managing Director, effective 1st August 2025.
Lastly, the company said its board has recommended that members seek enabling approval to raise up to Rs 5,000 crore through the issuance of equity shares, including via convertible bonds/debentures, through qualified institutional placement (QIP) or any other modes at the upcoming annual general meeting.
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.